Pharma 4.0 Continuous mRNA Drug Products Manufacturing
Continuous mRNA drugs manufacturing is perceived to nurture flow processes featuring quality by design, controlled automation, real time validation, robustness, and reproducibility, pertaining to regulatory harmonization. However, the actual adaptation of the latter remains elusive, hence batch-to-c...
Saved in:
Main Authors: | Andreas Ouranidis (Author), Christina Davidopoulou (Author), Reald-Konstantinos Tashi (Author), Kyriakos Kachrimanis (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Integrating Elastic Tensor and PC-SAFT Modeling with Systems-Based Pharma 4.0 Simulation, to Predict Process Operations and Product Specifications of Ternary Nanocrystalline Suspensions
by: Andreas Ouranidis, et al.
Published: (2021) -
Pharma 4.0-Artificially Intelligent Digital Twins for Solidified Nanosuspensions
by: Christina Davidopoulou, et al.
Published: (2022) -
Exploiting Pharma 4.0 Technologies in the Non-Biological Complex Drugs Manufacturing: Innovations and Implications
by: Vera Malheiro, et al.
Published: (2023) -
Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era
by: Andreas Ouranidis, et al.
Published: (2021) -
Polyelectrolyte Matrices in the Modulation of Intermolecular Electrostatic Interactions for Amorphous Solid Dispersions: A Comprehensive Review
by: Anastasia Tsiaxerli, et al.
Published: (2021)